Research programme: glaucoma therapeutics - Duska TherapeuticsAlternative Names: Glaucoma therapeutics research programme - Duska Therapeutics
Latest Information Update: 20 Feb 2009
At a glance
- Originator Duska Therapeutics
- Mechanism of Action Purinergic P2X7 receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Glaucoma
Most Recent Events
- 21 Jun 2005 Early research in Glaucoma in USA (unspecified route)